BioArctic ABBRCTF 84 PB Ratio is 13.16 as of Jul. 03, 2026, which is 5% above its 10-year median of 12.52. GuruFocus rates BRCTF with a GF Score™ of 84/100 and a GF Value™ of $49.01 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, BioArctic AB ranks worse than 89.66% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-03), BioArctic AB's share price is $35.00. BioArctic AB's Book Value per Share for the quarter that ended in Mar. 2026 was $2.66. Hence, BioArctic AB's PB Ratio of today is 13.16.
The historical rank and industry rank for BioArctic AB's PB Ratio or its related term are showing as below:
BRCTF'
s PB Ratio Range Over the Past 10 Years
Min: 2.95 Med: 12.52 Max: 40.38
Current: 12.67
During the past 11 years, BioArctic AB's highest PB Ratio was 40.38. The lowest was 2.95. And the median was 12.52.
BRCTF's PB Ratio is ranked worse than 89.66% of 1228
companies
in the Biotechnology industry
Industry Median: 2.97
vs BRCTF: 12.67
During the past 12 months, BioArctic AB's average Book Value Per Share Growth Rate was 13.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 35.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 26.60% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of BioArctic AB was 152.20% per year. The lowest was -8.10% per year. And the median was 8.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BioArctic AB PB Ratio Related Terms
BioArctic AB PB Ratio Historical Data
* Premium members only.
The historical data trend for BioArctic AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioArctic AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioArctic AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioArctic AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioArctic AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
BioArctic AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioArctic AB (BRCTF) has a PB Ratio of 13.16 as of Jul. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioArctic AB and its competitors. This is near median its historical median of 12.52. Over the past decade, BioArctic AB's PB Ratio has ranged from 2.95 to 40.38. According to the industry distribution chart, BioArctic AB ranks #1101 out of 1228 companies in the Biotechnology industry, placing it in the top 89.7%.
Is BioArctic AB's PB Ratio too high?
BioArctic AB's current PB Ratio of 13.16 is near median its 10-year median of 12.52. Over the past 10 years, this metric has ranged from a low of 2.95 to a high of 40.38. The Biotechnology industry median PB Ratio is 2.97. BioArctic AB's value of 13.16 is 343.1% above this industry median. Based on the distribution chart, BioArctic AB ranks #1101 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioArctic AB has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #1101 out of 1228 companies for PB Ratio. This places BioArctic AB in the lower half of its industry. The industry median PB Ratio is 2.97. BioArctic AB's value of 13.16 is 343.1% above this benchmark. Historically, BioArctic AB's own PB Ratio has ranged from 2.95 to 40.38 over the past decade. While the company's 10-year median is 12.52 vs. the industry median of 2.97, BioArctic AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioArctic AB's current PB Ratio of 13.16 is 343.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioArctic AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioArctic AB's current PB Ratio is 13.16, which is near median its own 10-year median of 12.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (BRCTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $49.01, compared to a current price of $35.00 — trading 28.6% below its estimated fair value. The current PB Ratio is 13.16, which is near median its 10-year median of 12.52 and 343.1% above the Biotechnology industry median of 2.97. BioArctic AB's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioArctic AB (BRCTF), the current PB Ratio is 13.16 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioArctic AB (BRCTF) Overvalued in 2026?
Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued.
The current stock price of $35.00 is trading 28.6% below its estimated GF Value™ of $49.01.
GuruFocus considers BioArctic AB to be Modestly Undervalued.
Key valuation signals for BRCTF:
PB Ratio: 13.16 (near median its 10-year median of 12.52)
GF Value™: $49.01 vs. price of $35.00 (28.6% below fair value)
Industry Position: 343.1% above the Biotechnology median (#1101 of 1228)
No single metric tells the full story. See the BRCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
84GF Score
Get the complete analysis for BRCTF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRCTF has been successfully added to your 
